Lilly grand jury investigation
This article was originally published in The Gray Sheet
Is focusing on Lilly's "compliance with FDA regulatory requirements affecting the company's manufacturing operations," Lilly says in a Feb. 19 release. The firm "believes that this inquiry arises out of a 1989 review that resulted in a voluntary agreement between Lilly and the FDA to strengthen the company's manufacturing quality systems." Lilly shut down one of its drug manufacturing facilities in August 1989 following receipt of a lengthy FD- 483 and reopened the plant in November of that year after signing an agreement with FDA. The investigation is being conducted through a Maryland grand jury.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.